{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:35:40Z","timestamp":1791498940895,"version":"4.3.4"},"reference-count":33,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving ibrutinib with or without rituximab for untreated MCL were evaluated for treatment toxicity, response, and survival, including outcomes in high-risk MCL (TP53 mutation\/deletion\/p53 overexpression, blastoid\/pleomorphic, or Ki67\u00a0\u2265 30%). A total of 149 patients from 43 participating centers were enrolled: 74.1% male, median age 75 years, 75.2% Eastern Cooperative Oncology Group status of 0 to 1, 36.2% high-risk, and 8.9% autologous transplant candidates. All patients received \u22651 cycle ibrutinib (median, 8 cycles), 39.0% with rituximab. Grade \u22653 toxicity occurred in 20.3%, and 33.8% required dose reductions\/delays. At 15.6-month median follow-up, 41.6% discontinued ibrutinib, 8.1% due to toxicity. Of 104 response-assessed patients, overall (ORR) and complete response (CR) rates were 71.2% and 20.2%, respectively. ORR was 77.3% (low risk) vs 59.0% (high risk) (P\u00a0= .05) and 78.7% (ibrutinib-rituximab) vs 64.9% (ibrutinib; P\u00a0= .13). Median progression-free survival (PFS) was 26.0\u00a0months (all patients); 13.7\u00a0months (high risk) vs not reached (NR) (low risk; hazard ratio [HR], 2.19; P\u00a0= .004). Median overall survival was NR (all); 14.8\u00a0months (high risk) vs NR (low risk; HR, 2.36; P\u00a0=\u00a0.005). Median post-ibrutinib survival was 1.4\u00a0months, longer in 41.9% patients receiving subsequent treatment (median, 8.6 vs 0.6\u00a0months; HR, 0.36; P\u00a0=\u00a0.002). Ibrutinib with or without rituximab was effective and well tolerated as first-line treatment of MCL, including older and transplant-ineligible patients. PFS and OS were significantly inferior in one-third of patients with high-risk disease and those unsuitable for post-ibrutinib treatment, highlighting the need for novel approaches in these groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011152","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T11:07:18Z","timestamp":1703156838000},"page":"1209-1219","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Ibrutinib as first-line therapy for mantle cell lymphoma: a\u00a0multicenter, real-world UK study"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5389-3741","authenticated-orcid":false,"given":"Ann","family":"Tivey","sequence":"first","affiliation":[{"name":"1The University of Manchester, Manchester, United Kingdom"},{"name":"2The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4545-8296","authenticated-orcid":false,"given":"Rohan","family":"Shotton","sequence":"additional","affiliation":[{"name":"1The University of Manchester, Manchester, United Kingdom"},{"name":"2The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"3Oxford University Hospitals NHS Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lewis","sequence":"additional","affiliation":[{"name":"4Plymouth Hospitals NHS Trust, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-840X","authenticated-orcid":false,"given":"Louise","family":"Stanton","sequence":"additional","affiliation":[{"name":"5University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Allchin","sequence":"additional","affiliation":[{"name":"6University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Walter","sequence":"additional","affiliation":[{"name":"6University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Miall","sequence":"additional","affiliation":[{"name":"6University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-1672","authenticated-orcid":false,"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[{"name":"7Torbay Hospital, Torquay, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Santarsieri","sequence":"additional","affiliation":[{"name":"8Cambridge University Hospitals, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-7174","authenticated-orcid":false,"given":"Rory","family":"McCulloch","sequence":"additional","affiliation":[{"name":"9Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bishton","sequence":"additional","affiliation":[{"name":"10University of Nottingham, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Beech","sequence":"additional","affiliation":[{"name":"11Nottingham University Hospitals, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Willimott","sequence":"additional","affiliation":[{"name":"12Norfolk and Norwich NHS Foundation Trust, Norwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fowler","sequence":"additional","affiliation":[{"name":"13Royal Cornwall Hospital NHS Trust, Truro, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bedford","sequence":"additional","affiliation":[{"name":"13Royal Cornwall Hospital NHS Trust, Truro, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Goddard","sequence":"additional","affiliation":[{"name":"14Sheffield Teaching Hospitals, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5600-1104","authenticated-orcid":false,"given":"Sam","family":"Protheroe","sequence":"additional","affiliation":[{"name":"15Stockport NHS Foundation Trust, Stockport, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angharad","family":"Everden","sequence":"additional","affiliation":[{"name":"13Royal Cornwall Hospital NHS Trust, Truro, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tucker","sequence":"additional","affiliation":[{"name":"13Royal Cornwall Hospital NHS Trust, Truro, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Wright","sequence":"additional","affiliation":[{"name":"14Sheffield Teaching Hospitals, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasavi","family":"Dukka","sequence":"additional","affiliation":[{"name":"15Stockport NHS Foundation Trust, Stockport, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Reeve","sequence":"additional","affiliation":[{"name":"16Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-011X","authenticated-orcid":false,"given":"Shankara","family":"Paneesha","sequence":"additional","affiliation":[{"name":"17University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Prahladan","sequence":"additional","affiliation":[{"name":"18East Suffolk and North Essex NHS Foundation Trust, Colchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hodson","sequence":"additional","affiliation":[{"name":"18East Suffolk and North Essex NHS Foundation Trust, Colchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Qureshi","sequence":"additional","affiliation":[{"name":"19University Hospital Coventry and Warwickshire NHS Foundation Trust, Coventry, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3086-7832","authenticated-orcid":false,"given":"Manasvi","family":"Koppana","sequence":"additional","affiliation":[{"name":"18East Suffolk and North Essex NHS Foundation Trust, Colchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Owen","sequence":"additional","affiliation":[{"name":"16Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kushani","family":"Ediriwickrema","sequence":"additional","affiliation":[{"name":"20University College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marr","sequence":"additional","affiliation":[{"name":"21Newcastle Teaching Hospitals NHS Foundation Trust, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Wilson","sequence":"additional","affiliation":[{"name":"22St Richard's Hospital, Chichester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lambert","sequence":"additional","affiliation":[{"name":"20University College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wrench","sequence":"additional","affiliation":[{"name":"23Guy's and St.Thomas' NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Burney","sequence":"additional","affiliation":[{"name":"24University Hospitals Bristol NHS Trust, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Knott","sequence":"additional","affiliation":[{"name":"24University Hospitals Bristol NHS Trust, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Talbot","sequence":"additional","affiliation":[{"name":"25University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gibb","sequence":"additional","affiliation":[{"name":"2The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lord","sequence":"additional","affiliation":[{"name":"7Torbay Hospital, Torquay, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Jackson","sequence":"additional","affiliation":[{"name":"7Torbay Hospital, Torquay, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Stern","sequence":"additional","affiliation":[{"name":"26Epsom and St Helier University Hospitals NHS Trust, Carshalton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Sutton","sequence":"additional","affiliation":[{"name":"27Gateshead Health NHS Foundation Trust, Gateshead, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Webb","sequence":"additional","affiliation":[{"name":"28Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marketa","family":"Wilson","sequence":"additional","affiliation":[{"name":"28Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Thomas","sequence":"additional","affiliation":[{"name":"28Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Norman","sequence":"additional","affiliation":[{"name":"29Manchester University NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5424-6776","authenticated-orcid":false,"given":"Elizabeth","family":"Davies","sequence":"additional","affiliation":[{"name":"29Manchester University NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lowry","sequence":"additional","affiliation":[{"name":"30Somerset NHS Foundation Trust, Taunton and Bridgwater, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-7934","authenticated-orcid":false,"given":"Jamie","family":"Maddox","sequence":"additional","affiliation":[{"name":"42South Tees Hospitals NHS Foundation Trust, Middlesborough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Phillips","sequence":"additional","affiliation":[{"name":"25University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Crosbie","sequence":"additional","affiliation":[{"name":"4Plymouth Hospitals NHS Trust, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Flont","sequence":"additional","affiliation":[{"name":"31York and Scarborough Teaching Hospitals NHS Foundation, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Nga","sequence":"additional","affiliation":[{"name":"32Airedale NHS Foundation Trust, Keighley, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Virchis","sequence":"additional","affiliation":[{"name":"33The Royal Free London NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa Guerrero","family":"Camacho","sequence":"additional","affiliation":[{"name":"34Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wunna","family":"Swe","sequence":"additional","affiliation":[{"name":"35Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Pillai","sequence":"additional","affiliation":[{"name":"36Countess of Chester Hospital NHS Foundation Trust, Chester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Rees","sequence":"additional","affiliation":[{"name":"37Frimley Health NHS Foundation Trust, Frimley, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bailey","sequence":"additional","affiliation":[{"name":"38Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Jones","sequence":"additional","affiliation":[{"name":"39Sherwood Forest Hospitals, Nottinghamshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Smith","sequence":"additional","affiliation":[{"name":"39Sherwood Forest Hospitals, Nottinghamshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Sharpley","sequence":"additional","affiliation":[{"name":"2The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hildyard","sequence":"additional","affiliation":[{"name":"40Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8502-6709","authenticated-orcid":false,"given":"Sajir","family":"Mohamedbhai","sequence":"additional","affiliation":[{"name":"20University College Hospital NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Nicholson","sequence":"additional","affiliation":[{"name":"41St Helens and Knowsley NHS Foundation Trust, Merseyside, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Moule","sequence":"additional","affiliation":[{"name":"37Frimley Health NHS Foundation Trust, Frimley, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshuman","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"1The University of Manchester, Manchester, United Kingdom"},{"name":"2The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-1548","authenticated-orcid":false,"given":"Kim","family":"Linton","sequence":"additional","affiliation":[{"name":"1The University of Manchester, Manchester, United Kingdom"},{"name":"2The Christie NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"issue":"16","key":"2024031114102639800_bib1","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024031114102639800_bib2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2024031114102639800_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024031114102639800_bib4","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"key":"2024031114102639800_bib5","unstructured":"International Traditional Medicine Clinical Trial Registry\n          . ISRCTN11038174: ENRICH Ibrutinib for Untreated Mantle Cell Lymphoma. Accessed 16 May 2023. https:\/\/www.isrctn.com\/ISRCTN11038174."},{"issue":"26","key":"2024031114102639800_bib6","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024031114102639800_bib7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024031114102639800_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"2024031114102639800_bib9","unstructured":"NHS England\n          . IBR5CV: National Cancer Drugs Fund (CDF) List Version 1.190. Accessed 7 June 2023. https:\/\/www.theacp.org.uk\/userfiles\/file\/resources\/covid_19_resources\/nhs-england-interim-treatment-options-during-the-covid19-pandemic-pdf-8715724381-6-jan-2021.pdf."},{"issue":"27","key":"2024031114102639800_bib10","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2024031114102639800_bib11","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024031114102639800_bib12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2024031114102639800_bib13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/bjh.17363","article-title":"Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients","volume":"193","author":"McCulloch","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2024031114102639800_bib14","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1097\/HS9.0000000000000529","article-title":"EHA\/ESMO Clinical Practice Guidelines for the management of malignant lymphoma: recommendations for the second phase of the COVID-19 pandemic","volume":"5","author":"Dreyling","year":"2021","journal-title":"Hemasphere"},{"issue":"1","key":"2024031114102639800_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024031114102639800_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40199-022-00444-w","article-title":"Efficacy and safety of ibrutinib in mantle cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Roufarshbaf","year":"2022","journal-title":"Daru"},{"issue":"3","key":"2024031114102639800_bib17","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2665-9913(21)00418-5","article-title":"Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients","volume":"4","author":"Boekel","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"2024031114102639800_bib18","doi-asserted-by":"crossref","first-page":"e0711","DOI":"10.1097\/HS9.0000000000000711","article-title":"Outcome of COVID-19 in patients with mantle cell lymphoma\u2014report from the European MCL Registry","volume":"6","author":"Tilch","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"2024031114102639800_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/2643-3230.BCD-21-0222","article-title":"CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity","volume":"3","author":"Shree","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"2024031114102639800_bib20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"2024031114102639800_bib21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clml.2018.07.282","article-title":"TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma","volume":"18","author":"Obr","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2024031114102639800_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2024031114102639800_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjh.17419","article-title":"Mantle cell lymphoma \u2013 advances in molecular biology, prognostication and treatment approaches","volume":"195","author":"Silkenstedt","year":"2021","journal-title":"Br J Haematol"},{"issue":"14","key":"2024031114102639800_bib24","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/bloodadvances.2022007247","article-title":"Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma","volume":"6","author":"Narkhede","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2024031114102639800_bib25","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"key":"2024031114102639800_bib26","author":"Pettitt","year":"2020"},{"issue":"3","key":"2024031114102639800_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2024031114102639800_bib28","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"2024031114102639800_bib29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2024031114102639800_bib30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch","year":"2020","journal-title":"Br J Haematol"},{"issue":"24","key":"2024031114102639800_bib31","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2019852368","article-title":"Acalabrutinib for mantle cell lymphoma","volume":"133","author":"Witzig","year":"2019","journal-title":"Blood"},{"issue":"21","key":"2024031114102639800_bib32","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2024031114102639800_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/fon-2020-0794","article-title":"A\u00a0phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma","volume":"17","author":"Dreyling","year":"2021","journal-title":"Future Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1209\/2217615\/blooda_adv-2023-011152-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1209\/2217615\/blooda_adv-2023-011152-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T10:10:58Z","timestamp":1710151858000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/5\/1209\/506677\/Ibrutinib-as-first-line-therapy-for-mantle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011152","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}